Antibody therapy of cancer

被引：1655
作者：
Scott, Andrew M. [1 ,2 ]
Wolchok, Jedd D. [3 ,4 ,5 ,6 ]
Old, Lloyd J. [4 ,5 ,6 ]
机构：
[1] Univ Melbourne, Ludwig Inst Canc Res, Melbourne, Vic 3084, Australia
[2] Austin Hosp, Ctr PET, Melbourne, Vic 3084, Australia
[3] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[4] Mem Sloan Kettering Canc Ctr, Ludwig Inst Canc Res, New York, NY 10065 USA
[5] Mem Sloan Kettering Canc Ctr, Ludwig Ctr Canc Immunotherapy, New York, NY 10065 USA
[6] Weill Cornell Med Coll, New York, NY 10065 USA
来源：
NATURE REVIEWS CANCER | 2012年 / 12卷 / 04期
基金：
英国医学研究理事会;
关键词：
METASTATIC COLORECTAL-CANCER; C-RECEPTOR POLYMORPHISMS; GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODY; PHASE-I; BREAST-CANCER; NEXT-GENERATION; KRAS MUTATIONS; DRUG-THERAPY; TRIAL;
D O I：
10.1038/nrc3236
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
引用
收藏
页码：278 / 287
页数：10
相关论文
共 55 条
[1]   Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].
Amado, Rafael G. ;
Wolf, Michael ;
Peeters, Marc ;
Van Cutsem, Eric ;
Siena, Salvatore ;
Freeman, Daniel J. ;
Juan, Todd ;
Sikorski, Robert ;
Suggs, Sid ;
Radinsky, Robert ;
Patterson, Scott D. ;
Chang, David D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634
[2]  
[Anonymous], ENCY IMMUNOLOGY 2 ED
[3]  
Asnacios Amani, 2009, Eur J Cancer, V45 Suppl 1, P332, DOI 10.1016/S0959-8049(09)70047-4
[4]   CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].
Beatty, Gregory L. ;
Chiorean, Elena G. ;
Fishman, Matthew P. ;
Saboury, Babak ;
Teitelbaum, Ursina R. ;
Sun, Weijing ;
Huhn, Richard D. ;
Song, Wenru ;
Li, Dongguang ;
Sharp, Leslie L. ;
Torigian, Drew A. ;
O'Dwyer, Peter J. ;
Vonderheide, Robert H. .
SCIENCE, 2011, 331 (6024) :1612-1616
[5]   Strategies and challenges for the next generation of therapeutic antibodies [J].
Beck, Alain ;
Wurch, Thierry ;
Bailly, Christian ;
Corvaia, Nathalie .
NATURE REVIEWS IMMUNOLOGY, 2010, 10 (05) :345-352
[6]   Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan [J].
Bibeau, Frederic ;
Lopez-Crapez, Evelyne ;
Di Fiore, Frederic ;
Thezenas, Simon ;
Ychou, Marc ;
Blanchard, France ;
Lamy, Aude ;
Penault-Llorca, Frederique ;
Frebourg, Thierry ;
Michel, Pierre ;
Sabourin, Jean-Christophe ;
Boissiere-Michot, Florence .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) :1122-1129
[7]   Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity [J].
Boland, William Kells ;
Bebb, Gwyn .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2009, 9 (09) :1199-1206
[8]   Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].
Brahmer, Julie R. ;
Drake, Charles G. ;
Wollner, Ira ;
Powderly, John D. ;
Picus, Joel ;
Sharfman, William H. ;
Stankevich, Elizabeth ;
Pons, Alice ;
Salay, Theresa M. ;
McMiller, Tracee L. ;
Gilson, Marta M. ;
Wang, Changyu ;
Selby, Mark ;
Taube, Janis M. ;
Anders, Robert ;
Chen, Lieping ;
Korman, Alan J. ;
Pardoll, Drew M. ;
Lowy, Israel ;
Topalian, Suzanne L. .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175
[9]   C-MET as a new therapeutic target for the development of novel anticancer drugs [J].
Canadas, Israel ;
Rojo, Federico ;
Arumi-Uria, Montserrat ;
Rovira, Ana ;
Albanell, Joan ;
Arriola, Edurne .
CLINICAL & TRANSLATIONAL ONCOLOGY, 2010, 12 (04) :253-260
[10]  
CARON PC, 1994, BLOOD, V83, P1760
123456